Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Liesenfeld

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Aktuelle Radiologie|May 1, 1995
[Synchronous bilateral testicular tumor: embryonal carcinoma and Leydig cell tumor]N Leipner, H Liesenfeld
Aktuelle Radiologie|September 1, 1996
[Early pulmonary changes caused by amiodarone]N Leipner, H Schüller, H Liesenfeld, et al.
Thrombosis and Haemostasis|March 9, 2012
A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgeryC Dansirikul, T Lehr, K-H Liesenfeld, et al.
Journal of Thrombosis and Haemostasis : JTH|October 7, 2011
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trialK-H Liesenfeld, T Lehr, C Dansirikul, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Aktuelle Radiologie|May 1, 1995
[Synchronous bilateral testicular tumor: embryonal carcinoma and Leydig cell tumor]N Leipner, H Liesenfeld
Aktuelle Radiologie|September 1, 1996
[Early pulmonary changes caused by amiodarone]N Leipner, H Schüller, H Liesenfeld, et al.
Thrombosis and Haemostasis|March 9, 2012
A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgeryC Dansirikul, T Lehr, K-H Liesenfeld, et al.
Journal of Thrombosis and Haemostasis : JTH|October 7, 2011
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trialK-H Liesenfeld, T Lehr, C Dansirikul, et al.
Pageof 1